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ttp://dx.doi.org/10.1016/j.ajpath.2013.06.030Tumor cell metastasis to the peritoneal cavity is observed in patients with tumors of peritoneal organs,
particularly colon and ovarian tumors. Following release into the peritoneal cavity, tumor cells rapidly attach
to the omentum, a tissue consisting of immune aggregates embedded in adipose tissue. Despite their
proximity to potential immune effector cells, tumor cells grow aggressively on these immune aggregates. We
hypothesized that activation of the immune aggregates would generate a productive antitumor immune
response in the peritoneal cavity. We immunized mice i.p. with lethally irradiated cells of the colon
adenocarcinoma line Colon38. Immunization resulted in temporary enlargement of immune aggregates, and
after challenge with viable Colon38 cells, we did not detect tumor growth on the omentum. When Colon38-
immunized mice were challenged with cells from the unrelated breast adenocarcinoma line E0771 or the
melanoma line B16, these tumors also did not grow. The nonspeciﬁc response was long-lived and not present
systemically, highlighting the uniqueness of the peritoneal cavity. Cellular depletions of immune subsets
revealed that NK1.1þ cells were essential in preventing growth of unrelated tumors, whereas NK1.1þ cells
and T cells were essential in preventing Colon38 tumor growth. Collectively, these data demonstrate that the
peritoneal cavity has a unique environment capable of eliciting potent speciﬁc and nonspeciﬁc antitumor
immune responses. (AmJPathol 2013, 183: 1318e1328; http://dx.doi.org/10.1016/j.ajpath.2013.06.030)Supported by NIH grants CA28332 (E.M.L.), HL069409 and AI061511
(T.D.R.), and T32 AI07825 (A.L.S.).
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process or ﬁnal disposition for this article.The peritoneal cavity is a unique immunologic environment
that includes immune aggregates present in the peritoneal
wall, mesentery, and omentum as well as free cells present in
the peritoneal ﬂuid.1,2 This ﬂuid, which mechanically acts
to lubricate organ movement, also distributes a variety of
immune subsets throughout the peritoneal cavity. The im-
mune cells present in the peritoneal ﬂuid are primarily
macrophages and B cells but also include other lymphocyte
and dendritic cell populations.3 These free-ﬂoating immune
cells have a dynamic relationship with the organized immune
aggregates also present in the peritoneal cavity.4,5 These
structures contain immune cell subsets similar to those in the
peritoneal ﬂuid but in a highly organized manner, similar to
many other tertiary immune structures.3,6,7 One site of these
immune aggregates, the omentum, is of particular interest
because of the high density of aggregates found there.
The omentum is a thin adipose tissue located in the peri-
toneal cavity that is appreciated as a guardian of the peritoneal
cavity, especially for its immunologic role in controllingstigative Pathology.
.infections. For example, peritoneal dialysis, which can in-
troduce bacteria into the cavity, leads to increases in the
number and size of omental immune aggregates, which
further increase on complications of peritonitis.8,9 In addition,
omental immune aggregates are the primary site of leukocyte
extravasation in models of peritonitis.10,11 Furthermore,
bacteria are rapidly sequestered in the omentum shortly after
introduction to the peritoneal cavity,12 a process that slows
bacterial dissemination throughout the peritoneal cavity.8
Collectively, these data suggest that omental immune aggre-
gates are capable of responding against foreign pathogens.
Similar to bacterial localization to the omentum, fol-
lowing tumor cell metastasis to the peritoneal cavity, the
initial and most common site of tumor formation is the
Peritoneal Antitumor Immunityomentum.7 Tumor cell metastasis to the peritoneal cavity is
generally a poor prognostic indicator, and limited effective
therapies are available to diagnosed individuals.13,14
Omental metastasis is a common occurrence in individuals
diagnosed as having cancers of the ovary and colon as well
as other peritoneal organs.15,16 It is speciﬁcally immune
aggregates to which metastasizing cells originally bind and
subsequently divide.7 Tumor growth on the omentum is
suggested to be a result of preferential binding to this site
and the presence of factors that promote tumor growth.7,17,18
After tumor formation on the omentum, tumor cells often
further disseminate to other sites in the peritoneal cavity, as
well as systemically, further propagating disease.
Despite data demonstrating the immune capabilities of the
omentum,4,6 the omental immune response to tumor metas-
tasis is relatively understudied. Limited work shows that after
cells adhere to the omentum, the vasculature of omental
immune aggregates is well-suited to supporting rapid tumor
growth. Under normal conditions, the vasculature of omental
immune aggregates exhibits a phenotype that may be capable
of rapid expansion after an immunologic stimulus, which is
exploited by metastasizing tumor cells.7 Despite the abun-
dance of immune cells present at the site of tumor growth,
a productive immune response does not occur naturally, and
tumors grow progressively.3,19
In an attempt to determine whether the omental immune
microenvironment is capable of promoting antitumor re-
sponses, we immunized mice with lethally irradiated tumor
cells. Because the omentum is the initial site of tumor cell
binding, i.p. immunization with these lethally irradiated
tumor cells allows us to target the omentum to potentially
generate an antitumor immune response. Herein, we found
that i.p. immunization with lethally irradiated tumor cells led
to the production of an antitumor immune response that was
effective in controlling the growth of both speciﬁc and
unrelated tumors after a secondary challenge with viable
tumor cells. The nonspeciﬁc antitumor response was unique
to the peritoneal cavity and was sustained for 60 days after
immunization. In addition, depletion of NK1.1þ cells
reversed the protective effects elicited by immunization only
when challenged with an unrelated tumor challenge. In
contrast, depletion of NK1.1þ cells and conventional T-cell
populations was required to reverse the protective effects
against speciﬁc tumor challenge. Thus, activation of perito-
neal NK1.1þ cells in addition to conventional T-cell pop-
ulations may have potent antitumor capabilities that could be
exploited to beneﬁt patients therapeutically.
Materials and Methods
Mice and Cell Lines
C57BL/6 and BALB/c mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). B6.129S2-Igh-6
tm1Cgn mice (mMT B cell KO) were a gift from Dr. Frances
Lund (University of Rochester). All the mice were treatedThe American Journal of Pathology - ajp.amjpathol.orgfollowing the guidelines for the humane treatment of animals
as approved by the University of Rochester Committee on
Animal Resources. Colon38, a murine colon adenocarci-
noma, and E0771, a murine mammary adenocarcinoma, were
gifts from Dr. Edward Brown (University of Rochester). The
B16-F0 cell line was purchased from the ATCC (Manassas,
VA). The Line1 cell line was a gift fromDr. John Yuhas (Oak
Ridge National Laboratory) and the EMT6 line from Dr.
Robert Sutherland (Ontario Institute for Cancer Research).
Colon38/GFP, EMT6/GFP, and L1/GFP were generated by
Lipofectamine reagent (Invitrogen, Grand Island, NY)
transfection of parental lines with the pEGFP plasmid as
previously described.7 All the cell lines were tested using
PCR-based testing (University of Missouri Research Animal
Diagnostic Laboratory, Columbia, MO) and were found to be
negative for a panel of mouse pathogens, including myco-
plasma. The lines were maintained in MAT/P media (US
patent No. 4.816.401) supplemented with 100 U/mL1
penicillin, 100 mg/mL1 streptomycin (Sigma-Aldrich, St.
Louis, MO), and no fetal calf serum to avoid cross-reactive
immune responses against serum proteins.
Major Histocompatibility Complex Class I Analysis
B16, Colon38, and E0771 cells were plated at a concentration
of 2.5  106 cells/mL in 2 mL of MAT/P media. Cells were
incubated for 72 hours in the presence of 20 ng/mL of mouse
interferon gamma (IFN-g) (PeproTech, Rocky Hill, NJ) or
vehicle control. After IFN-g treatment, cells were trypsinized,
stained with antieH-2Kb (clone AF6-88.5) for 1 hour, and
analyzed by ﬂow cytometery using a BD FACSCanto cytom-
eter (BDBiosciences, San Jose, CA).Datawere analyzedusing
FlowJo software version 7.6 (Tree Star Inc., Ashland, OR).
Immunization and Tumor Challenges
C57BL/6 mice were immunized by injecting 1  106
Colon38 cells treated with 100 Gy of ionizing radiation i.p.
Mice were challenged 14 or 60 days after immunization
with 1  105 Colon38 cells, 1  105 B16-F0 cells, or 1 
106 E0771 cells either i.p. or i.m. in the left thigh. Mice that
had been challenged i.p. were sacriﬁced after 3 or 7 days,
and omenta were processed for analysis by whole-mount
histology, ﬂow cytometry, and/or colony-forming assay as
described below. Tumor growth in mice that had been
challenged i.m. was monitored over time by measuring the
mean thigh diameter as previously described.20
BALB/c mice were treated in a similar manner using 5 
106 irradiated EMT6 cells to immunize and 1  105 EMT6/
GFP or Line1/GFP cells to challenge.
Whole-Mount Histologic Analysis and Image
Processing and Analysis
Omenta were removed from mice after sacriﬁce and were
stained with ﬂuorescently conjugated antibodies as previously1319
Sedlacek et aldescribed3,7 or were left unlabeled. Brieﬂy, whole omenta were
mounted on glass slides and imaged using a ﬂuorescence
microscope equipped with a monochrome CCD digital camera.
To calculate tumor burden in mice that had been chal-
lenged with GFP-expressing tumor cells, images covering
the entire omentum were captured and assembled to create
a montage in bright ﬁeld and GFP ﬂuorescence. Image-Pro
software version 5.0 (Media Cybernetics Inc., Rockville,
MD) was used to determine percentage of tumor burden as
follows: bright ﬁeld compositions were used to designate
the area of the omentum as the area of interest. Generated
areas of interest were applied to GFP ﬂuorescence compo-
sitions to calculate a percentage of area that is GFP positive.
The antibodies used were obtained from BD Biosciences
or eBioscience Inc. (San Diego, CA) and included anti-CD4
(clone RM4-5), anti-CD8a (clone 53-6.7), anti-CD19 (clone
1D3), anti-CD31 (clone MEC13.3), and anti-F4/80 (clone
BM8).
Flow Cytometric Analysis
Omenta were processed into single-cell suspensions by incu-
bation of whole omenta in collagenase D (Sigma-Aldrich) for
40 minutes at 37C with rotation. Samples were washed with
HBSS (Sigma-Aldrich), counted, and blocked using BD Fc
Block (BD Biosciences). Samples were stained for 1 hour. If
intracellular staining was performed, cells were ﬁxed with BD
Cytoﬁx/Cytoperm (BD Biosciences) for 20 minutes, and then
intracellular staining was performed for 1 hour. Samples were
then analyzed using a BD FACSCanto cytometer (BD Bio-
sciences) and FlowJo software version 7.6 (Tree Star Inc.).
The antibodies used were obtained from BD Biosciences
or eBioscience Inc. and were anti-CD3ε (clone 145-2C11),
anti-CD4 (clones GK1.5 and RM4-4), anti-CD8a (clone 53-
6.7), anti-CD8b (clone H35-17.2), anti-CD11b (clone M1/
70), anti-CD11c (clone HL3), anti-CD19 (clone 1D3), anti-
CD107a (clone 1D4B), anti-B220 (clone RA3-6B2), anti-
F4/80 (clone BM8), antiegranzyme B (clone NGZB),
antieIFN-g (clone XMG1.2), anti-NK1.1 (clone PK136),
anti-NKG2D (clone CX5), anti-NKp46 (clone 29A1.4),
anti-perforin (clone eBioOMAK-D), and antietumor
necrosis factor a (TNF-a) (clone MP6-XT22).
Colony-Forming Assays
Colony-forming assays were performed as previously de-
scribed.21,22 Brieﬂy, omenta were removed from mice and
single-cell suspensions were obtained by collagenase dissoci-
ationas describedpreviously inMaterials andMethods. Single-
cell suspensions were then serially diluted in MAT/P media
supplemented with 5% fetal calf serum (Hyclone Laboratories,
Lakewood, NJ) and plated in triplicate in 60-mm tissue cul-
tureetreated plates. Plates were then incubated at 37C for 7 to
10 days to allow for the formation of colonies and were
enumerated using crystal violet. Samples in which no colonies
were present were given a value of 1 for graphing purposes.1320In Vivo Cell Depletions
Antibody depletion using aCD4 (clone GK1.5), aCD8
(clone 53-6.7), or aThy1 (clone T24) was performed by i.v.
injection of 200 mg of antibody per mouse every 4 days
starting 5 days before live tumor challenge. Antibody
depletion using aNK1.1 (clone PK136) was performed by
i.v. injection of 500 mg of antibody per mouse 5 days before
live tumor challenge and 200 mg of antibody per mouse 1
day before and 3 days after live tumor challenge. Depletion
of macrophages was performed by i.p. injection of 200 mL
of 1 clodronate liposomes23 4 and 2 days before live
tumor challenge.
Statistical Analysis
Data were plotted and statistical analysis was run using
GraphPad Prism software version 4 (GraphPad Software
Inc., San Diego, CA). Student’s t-test or analysis of variance
followed by a Bonferoni post-test was used where appro-
priate. P < 0.05 was considered signiﬁcant.
Results
Intraperitoneal Immunization Results in Temporary
Expansion of Omental Immune Aggregates
We hypothesized that immunization using lethally irradiated
tumor cells would result in the induction of an antitumor
immune response on the omentum. To assess the omental
response to such an immunization, mice were injected i.p.
with Colon38 cells that had been lethally irradiated with 100
Gy (10,000 rad) in vitro. At various time points after immu-
nization, omenta were harvested for whole-mount histologic
analysis. Naive immune aggregates were visible as clusters of
lymphocytes and macrophages supported by dense vascular
networks (Figure 1A). Enlarged immune aggregates were
evident 7 days after immunization (Figure 1C), followed by
a return to approximately naive size by day 14 (Figure 1E). In
accordancewith the visual increase in size, the number of total
immune (CD45þ) cells recovered per omentum was also
increased at day 7 and subsequently reduced at day 14
(Table 1). Seven days after immunization, the time pointwhen
the density of omental cells was the highest, the weight of the
omentum was also signiﬁcantly elevated over that of naive
omenta and omenta 14 days after immunization (Table 1).
Omenta were also analyzed by ﬂow cytometry to better
classify the immune cell types on the omentum that were
responding to immunization. Representative ﬂow cytometry
panels are shown in Supplemental Figure S1. Naive immune
aggregates are composed primarily of macrophages and B
cells, with smaller populations of T cells, NK1.1þ cells, and
dendritic cells (Figure 1B). All immune cell subsets expand 7
days after immunization; however, at this time point, CD8þ T
cells, followed by CD4þ T cells, constitute a proportionally
larger fraction of immune cells compared with naive omentaajp.amjpathol.org - The American Journal of Pathology
Figure 1 Omental immune aggregates showed
evidence of an active immune response after i.p.
immunization with lethally irradiated Colon38.
Mice were immunized i.p. with 5  106 lethally
irradiated Colon38 cells and were sacriﬁced 7 or 14
days after immunization. Omenta were harvested
from naive mice (A) or from mice 7 days (C) or 14
days (E) after immunization and were stained with
aCD31 (green), aF4/80 (red), and aCD4/aCD8/
aCD19 (blue) and were analyzed by whole-mount
microscopy. Single-cell suspensions were then
stained for ﬂow cytometry to distinguish major
immune cell subsets present on the omenta of
naive mice (B) or mice 7 days (D) or 14 days (F)
after immunization. DC, dendritic cell. Data are
representative of two experiments (n Z 4 to 5
mice per group).
Peritoneal Antitumor Immunity(Figure 1D). Similar to immune aggregate size and cellularity,
by day 14, the immune cell composition of immunized omenta
had returned to approximately naive levels, except forCD8þT
cells, which remained signiﬁcantly increased (Figure 1F).
Thus, immunizationwith lethally irradiated tumor cells results
in temporary enlargement of omental immune aggregates,
which contain increased proportions of CD8þ T cells.
Immunization Prevents the Growth of Both Speciﬁc
and Unrelated Tumors on the Omentum
To determine whether the immune response generated by
immunization is capable of mediating an effect on tumorTable 1 Immune Aggregates Are Temporarily Enlarged after
Immunization
Days after
immunization
CD45þ cells per
omentum
Omental
weight (mg)
0 (naive) 3.5  1.7  105 11.6  3.2
7 26.0  6.3  105* 29.6  7.5*
14 7.1  3.6  105 11.9  4.7
Data are given as means  SD.
*P < 0.001 compared with naive as determined by one-way analysis of
variance followed by a Bonferroni posttest. n Z 4 to 8 mice per group.
The American Journal of Pathology - ajp.amjpathol.orggrowth, we challenged immunized mice i.p. with live
Colon38 cells. Mice were challenged 14 days after immuni-
zation, a time when the omentum is no longer at the peak of
the initial immune response. This time point was chosen to
avoid analyzing the response generated by the temporary
inﬂammation caused by immunizationwith lethally irradiated
cells. Mice were sacriﬁced 7 days after challenge, and tumor
growth was assessed by two different methods. First, mice
were challenged with GFP-expressing Colon38 (C38/GFP),
and tumor burden was assessed by ﬂuorescence microscopy
as described in Materials and Methods. Omenta harvested
from immunized mice did not exhibit the large tumor burden
that was present on omenta from mice receiving a vehicle
immunization (unimmunized) and exhibited very little GFP
ﬂuorescence, indicating little to no tumor burden (Figure 2,
A and B). Thus, immunization prevented the growth of
Colon38. To complement the whole-mount method, we also
examined tumor burden by colony-forming assay. Similar to
the ﬂuorescence data, we detected viable tumor cells on the
omentum 7 days after challenge, whereas unimmunized
omenta contained abundant tumor cells (Figure 2C). These
data indicate that i.p. immunization with lethally irradiated
tumor cells results in an effective antitumor response capable
of preventing tumor growth on the omentum.1321
Figure 2 Immunization with lethally irradiated Colon38 prevented the
growth of Colon38 on the omentum (OM) after tumor challenge. Mice were
immunized i.p.with 5 106 lethally irradiated Colon38 cells orwere treatedwith
vehicle and challenged i.p. 14 days later with 1 105 Colon38/GFP (A and B) or
Colon38 (C). OMwereharvested7days after challenge.WholeOMwere imagedby
whole-mount ﬂuorescence microscopy (A), and the percentage area of the OM
that was GFPþ was determined (B). C: OM were also collagenase digested into
single-cell suspensions, and tumor burden was determined by colony-forming
assay. Each dot represents an individual mouse, and lines indicate the mean
(B and C). Statistical signiﬁcance was determined by Student’s t-test. Data are
representative of four experiments (nZ 3 mice per group).
Figure 3 Immunization prevented the growth of unrelated tumors on the
omentum (OM) of C57BL/6 and BALB/c mice. C57BL/6 mice were immunized
i.p. with 5  106 lethally irradiated Colon38 cells (A) or were treated with
vehicle and challenged i.p. 14 days laterwith 1 106 E0771 cells (B) or 1 105
B16 cells (C). OM were harvested 7 days after tumor challenge, and tumor
burden was assessed by colony-forming assay. BALB/c mice were immunized
i.p. with 5 106 lethally irradiated EMT6 cells (D) or were treated with vehicle
and challenged i.p. 14 days later with 1  105 EMT6/GFP cells (E) or 1  105
Line1/GFP cells (F). Eachdot represents an individualmouse, and lines indicate
the mean (B, C, E, and F). Statistical signiﬁcance was determined by Student’s
t-test. Data are combined from two experiments (nZ 2 to 3 mice per group).
Sedlacek et alTo analyze the speciﬁcity of the antitumor response after
immunization with lethally irradiated tumor cells, mice that
had been immunized with Colon38 were challenged with
an alternative syngeneic tumor cell line: either E0771
(a spontaneously arising mammary carcinoma) or B16.F0 (a
spontaneously arising melanoma) (Figure 3A). Regardless
of which tumor was used to challenge, mice that had been
immunized with Colon38 were capable of rejecting E0771
and B16 (Figure 3, B and C). To determine whether this
lack of speciﬁcity was unique to C57BL/6 mice immunized
with Colon38, we repeated the immunization and challenge
protocol in BALB/c mice using EMT6 (a mammary car-
cinoma) to immunize and EMT6/GFP or Line1/GFP (a
spontaneous lung carcinoma) to challenge mice (Figure 3D).
Similar to immunization with Colon38, mice that were i.p.
immunized with lethally irradiated EMT6 could prevent the
growth of speciﬁc (EMT6) and unrelated (Line1) tumor on
the omentum (Figure 3, E and F). Thus, we could demon-
strate nonspeciﬁc tumor protection in two different strains of
mice against tumors of varying origin.
Speciﬁc and Unrelated Tumor Control Still Exists at
Least 60 Days after Immunization
We next examined the longevity of the antitumor response af-
ter immunization. If the speciﬁc and/or nonspeciﬁc antitumor
responses resulted in the development of immunologic1322memory, we would expect that mice challenged at a later time
point would still fail to develop tumor growth on the omentum.
Thus, mice were immunized and rested for 60 days instead
of 14 days and then were challenged with either Colon38
(speciﬁc) or B16 (unrelated) tumor cells (Figure 4A). As ex-
pected, mice that were challenged with Colon38 60 days
after immunization could still prevent tumor growth on the
omentum (Figure 4B). Even after 60 days, mice that were
challengedwith an unrelated tumor challenge (B16) also could
prevent tumor growth on the omentum (Figure 4C). Antitumor
responses were also observedwhenmicewere challengedwith
E0771 60 days after immunization (data not shown). These
data demonstrate that the nonspeciﬁc antitumor response is not
transient and is, indeed, long-lived.
Protection against Unrelated Tumor Challenge Is Not
Systemic
To determine whether the nonspeciﬁc antitumor response is
localized to the peritoneal cavity or whether it is a systemicajp.amjpathol.org - The American Journal of Pathology
Figure 4 Speciﬁc and nonspeciﬁc tumor immunity was long-lived. A:
Mice were immunized i.p. with 5  106 lethally irradiated Colon38 cells or
were treated with vehicle and challenged i.p. 60 days later with 1  105
Colon38 cells (B) or 1  105 B16 cells (C). Omenta (OM) were harvested 7
days after tumor challenge, and tumor burden was assessed by colony-
forming assay. Each dot represents an individual mouse, and lines indicate
the mean (B and C). Statistical signiﬁcance was determined by Student’s
t-test. Data are combined from two experiments (nZ 2 to 3 mice per group).
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Peritoneal Antitumor Immunityeffect, mice were immunized i.p. with irradiated Colon38 as
before and were challenged i.m. in the hind ﬂank with either
Colon38 or E0771 (Figure 5A). Tumor growth was then
monitored over time by measuring mean thigh diameter. As
expected, mice that had been immunized and challenged
with Colon38 had no measureable tumor growth in the thigh
(Figure 5B), indicating a systemic immune response. Unlike
the results in the peritoneal cavity, mice that were chal-
lenged with unrelated E0771 i.m. developed large tumors
regardless of whether they were immunized (Figure 5C).
These data indicate that whereas the speciﬁc antitumor
response after immunization is systemic, the nonspeciﬁc
antitumor response is not.2 4 6 8 10 12 14 16 18 20
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Figure 5 Nonspeciﬁc tumor immunity was not found peripherally. Mice
were immunized i.p. with 5  106 lethally irradiated Colon38 cells (A) or
were treated with vehicle and challenged i.m. in the hind ﬂank 14 days
later with 1  105 Colon38 cells (B) or 1  106 E0771 cells (C). Tumor
growth was monitored over time by measuring mean thigh diameter. Data
are representative of two experiments (n Z 3 mice per group).NK1.1þ Cells Are Necessary to Mediate Unrelated
Tumor Protection
We next sought to determine which cell type(s) was
responsible for preventing unrelated tumor growth on the
omentum after immunization. We focused on the natural
killer (NK) and NK T (NKT) cell populations owing to their
reported antitumor functions.24e26 Therefore, we depleted
NK and NKT cells with anti-NK1.1 just before challenge
with Colon38 or E0771 (during the effector phase). This
procedure routinely resulted in 80% knockdown of NK1.1þ
cells on the omentum. In mice challenged with unrelated
E0771, we observed that depletion of NK1.1þ cells reversed
the protective effects of immunization, and tumor growth was
apparent on the omentum (Figure 6B), demonstrating that
NK1.1þ cells are necessary during the effector phase to
prevent the growth of unrelated E0771 tumor after immuni-
zation. Flow cytometry analysis of H-2Kb surface expression
demonstrated that the tumor cell lines used express major
histocompatibility complex class I at varying levels that canThe American Journal of Pathology - ajp.amjpathol.orgbe increased in the presence of an inﬂammatory environment,
such as exposure to IFN-g (Supplemental Figure S2), sug-
gesting that NK cell recognition is not due to lack of major
histocompatibility complex class I expression. Mice that
were challenged with speciﬁc Colon38 had no omental tumor
burden regardless of the presence of NK1.1þ cell populations
(Figure 6A). This indicated that although NK1.1þ cells may
be playing a role in tumor prevention nonspeciﬁcally (as
demonstrated in E0771-challenged mice), on their own,
NK1.1þ cells were not necessary to prevent the growth of
speciﬁc Colon38 and that another cell population(s) was
equally effective in controlling speciﬁc tumor growth.
Because speciﬁc tumor control was still apparent after
depletion with anti-NK1.1, we hypothesized that i.p. im-
munization with lethally irradiated tumor cells was inducing
a speciﬁc and nonspeciﬁc antitumor immune response.1323
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Figure 6 NK1.1þ cells were necessary to prevent the growth of E0771
after immunization. Mice were immunized i.p. with 5 106 lethally irradiated
Colon38 cells or were treated with vehicle. Before challenge, NK and NKT cells
were depleted using aNK1.1. Mice were then challenged i.p. 14 days after
immunization with 1  105 Colon38 cells (A) or 1  106 E0771 cells (B).
Omenta (OM) were harvested 7 days after tumor challenge, and tumor burden
was assessed by colony-forming assay. Each dot represents an individual
mouse, and lines indicate the mean. Statistical signiﬁcance was determined
by two-way analysis of variance followed by a Bonferroni posttest. Data are
representative of two experiments (nZ 3 mice per group). ***P < 0.001.
Sedlacek et alDepletion of macrophages (70% depletion) did not alter
tumor protection against speciﬁc or unrelated tumor chal-
lenges (Supplemental Figure S3, A and B). Furthermore,
immunized mMT B cell KO mice were capable of preventing
tumor growth, to the same extent as wild-type mice
(Supplemental Figure S3, C and D), although in unimmu-
nizedmMTBcell KOmice, tumors grewprogressively. These
mice exhibited a 99% reduction in the number of omental
CD19þ B cells (data not shown). Previous reports looking at
immunization with lethally irradiated tumor cells outside the
peritoneal cavity demonstrated that CD4þ and CD8þ T cells
are necessary for speciﬁc antitumor immunity.27 Depletion of
either CD4þ (75% depletion) or CD8þ (70% depletion) T
cells alone did not alter the protective effect of immunization,
and no tumor growth was detected on the omentum after
speciﬁc tumor challenge (Supplemental Figure S3, E and F);
simultaneous depletion of CD4þ and CD8þ T cells using1324anti-Thy1 had no effect on speciﬁc tumor growth
(Supplemental Figure S3G). Depletion using antieThy-1
resulted in 70% to 80% knockdown of CD4þ and CD8þ T
cells and no depletion of NK1.1þ cells. In addition, depletion
of either CD8þ and NK1.1þ cells (Supplemental Figure S3H)
or CD4þ andNK1.1þ cells (Supplemental Figure S3I) did not
result in tumor growth after immunization. It was only
following depletion of CD4þ T cells, CD8þ T cells, and
NK1.1þ cells that speciﬁc tumor growth was observed in
immunized mice (Figure 7).
Because an NK1.1þ cell population was capable of pre-
venting the growth of both speciﬁc and unrelated tumor chal-
lenges, we further examined the possible role for NK cells in
preventing tumor growth after immunization. We examined
expression of the NK cell activating ligand NKG2D on omen-
tal NK cells after i.p. immunization with lethally irradiated
Colon38 and challenge with unrelated E0771 (Supplemental
Figure S4A). Mice that had been immunized, regardless of
challenge or not, exhibited increased NK cell expression of
NKG2DcomparedwithNK cells fromnaivemice. In addition,
challenge alone did not increaseNKcell expression ofNKG2D
(Supplemental Figure S4, B and C). These data are consistent
with a possible role for the activating ligand NKG2D in pre-
venting tumor growth after immunization.
Omental NK Cells Are Unique
We hypothesized that because the NK1.1þ celledependent,
nonspeciﬁc antitumor response seemed to be localized to the
peritoneal cavity and omentum that omental NK cells may have
a uniquely activated phenotype. Thus, we examined the basal
expression of various activation and effector proteins on splenic
and omental NK cells from naive mice. Omental NK cells
expressed higher levels of the natural cytotoxicity receptor
NKp46 (Supplemental Figure S5A). In addition, omental NK
cells had higher surface expression of the endosomal marker
CD107a (Supplemental Figure S5B). Surface expression of
CD107a indicates cellular secretion, suggesting that more
omental NK cells may secrete higher levels of effector proteins
basally. Thus, we also examined the basal intracellular ex-
pression of cytokine effector proteins and cytolytic effector
proteins. A higher percentage of omental NK cells expressed
TNF-a (Supplemental Figure S5C) and IFN-g (data not shown)
compared with splenic NK cells. In contrast, omental and
splenic NK cells expressed similar levels of the cytolytic
proteins granzyme B (Supplemental Figure S5D) and perforin
(data not shown). These data suggest that omentalNKcellsmay
bemoreprone to cytokine secretionbasally.Consistentwith this
hypothesis, the omentum contains a substantial population of
CD11cþB220þ NK cells (Supplemental Figure S5E), which
have been identiﬁed to be high cytokine producers in systems
of viral infection.
Collectively, this indicates that in the peritoneal cavity,
immunization induces a unique NK1.1þ cellemediated
response that is capable of broadly preventing the growth of
both speciﬁc and unrelated tumors potentially by increasedajp.amjpathol.org - The American Journal of Pathology
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Figure 7 T cells and NK1.1þ cells were necessary to prevent the growth
of speciﬁc Colon38 after immunization. Mice were immunized i.p. with 5 
106 lethally irradiated Colon38 cells or were treated with vehicle. Before
challenge, mice were treated with a combination of aCD4, aCD8, and
aNK1.1. Mice were then challenged i.p. 14 days after immunization with 1
 105 Colon38 cells. Omenta (OM) were harvested 7 days after tumor
challenge, and tumor burden was assessed by colony-forming assay. Each
dot represents an individual mouse, and lines indicate the mean. Statistical
signiﬁcance was determined by two-way analysis of variance followed by
a Bonferroni posttest.
Peritoneal Antitumor Immunitysignaling through the activating ligand NKG2D. In addition,
immunization also induces a CD4þ/CD8þ T-cellemediated
response that is capable of controlling the growth of speciﬁc
Colon38 but not unrelated E0771.Figure 8 Intraperitoneal immunization resulted in local antitumor
immunity that can prevent the growth of speciﬁc and unrelated tumor
challenges (green) as well as systemic antitumor immunity that is capable
of preventing the growth of speciﬁc tumor challenge (red). In the perito-
neal cavity, the omentum contains populations of immune cells localized in
immune aggregates that are necessary for both speciﬁc and nonspeciﬁc
antitumor immunity. After immunization, NK1.1þ cells were capable of
preventing the growth of speciﬁc and unrelated tumors, whereas T cells
were capable of preventing the growth of a speciﬁc tumor challenge only.Discussion
Herein, we generated an antitumor immune response that
involves a peritoneal, nonspeciﬁc, NK1.1þ cellemediated
response and a systemic, speciﬁc, T-cellemediated response
(Figure 8). The nonspeciﬁc immune response seems to be
localized to the peritoneal cavity and is not effective against
tumor challenge at a distal site. In contrast, the speciﬁc
immune response generated by immunization in the peri-
toneal cavity is capable of preventing tumor growth locally
on the omentum and systemically, as observed by i.m.
challenge. In addition, different cell populations mediate the
speciﬁc and nonspeciﬁc immune responses to these tumor
challenges. Depletion of NK1.1þ cells alone results in only
the growth of the unrelated tumor challenge, demonstrating
that another cell type(s) is capable of controlling the growth
of the speciﬁc tumor challenge. To observe speciﬁc tumor
growth after immunization, it is necessary to deplete the
effector cells of both the speciﬁc and nonspeciﬁc responses.
Thus, it is only following depletion of CD4þ, CD8þ, and
NK1.1þ cells that Colon38 grows in immunized mice.
Although we demonstrated that NK1.1þ cells are required
to mediate this nonspeciﬁc antitumor immune response in the
peritoneal cavity, it is unclear whether NK1.1þ cellsThe American Journal of Pathology - ajp.amjpathol.orgthemselves in the peritoneal cavity are distinctive or whether
another cell type exclusive to the peritoneal cavity is capable
of inducing this nonspeciﬁc response in NK1.1þ cells. The
peritoneal cavity is enriched for many unique cell populations
that may be involved in or inﬂuencing activation of these
NK1.1þ cells. This is of particular interest when considering
that the studies looking at various cellular depletions focused
on depletion only during the challenge phase and notwhen the
initial immune response to immunization was greatest. For
example, a larger portion of T cells in the peritoneal cavity
express markers indicative of activation, such as CD44 and
CXCR3, compared with other lymphoid organs.28,29 These
activated T cells produce increased levels of cytokines,
including IFN-g, following T cell receptor stimulation,
which, in this model, could account for the activation of
NK1.1þ cells to elicit antitumor responses. This hypothesis is
consistent with published data by Tietze et al,30 who
demonstrated that immunotherapy (aCD40/IL-2) results in T-
cell activation and a reduction in tumor growth even when T
cells cannot recognize tumor cells.30
Previous reports have found that the antitumor response
induced by lethally irradiated tumor cells outside the peri-
toneal cavity depends on T cells.27 These same studies,1325
Sedlacek et alhowever, did not demonstrate a critical role for NK cells. In
the present model of immunization, T-cell populations are
similarly induced to elicit antitumor immune responses;
however, the NK1.1þ cell response is highly unique because
it can control both speciﬁc and unrelated tumor challenges.
Typically, NK cells are triggered to lyse target cells
following an imbalance in triggering of activating and
inhibitory receptors. Thus, NK cells can be activated by
either loss of ligands that trigger inhibitory receptors or up-
regulation of ligands that trigger activating receptors. Both
of these processes have been reported to occur in tumor
cells. Many ligands for activating NK cell receptors are up-
regulated in response to cellular stress, such as MULT-1,
RAE1, and H60, which are recognized by NKG2D.31e33
Thus, the observed increase in NKG2D expression after
immunization may contribute to tumor cell death following
either speciﬁc or unrelated tumor challenge. In addition to
the gain of activating ligands, many tumor cells express low
levels of major histocompatibility complex class I mole-
cules, which, when present, trigger inhibitory receptors.34,35
The clearance of E0771 is NK1.1þ cell dependent. This cell
line expresses abundant surface major histocompatibility
complex class I molecules and, thus, is not likely recognized
by NK cells owing to their absence. It is more probable that
immunization increases the expression of activating ligands
on peritoneal NK cells or increases NK cell susceptibility to
activating cell ligand triggering.
In addition to activating and inhibitory receptors, NK cells
can be activated by exposure to cytokines. Although stimu-
lation under either Th1 or Th2 conditions activates NK cells
against tumors,36 exposure to Th1 cytokines, such as IL-12,
along with IL-15 and IL-18, increases NK cell survival
in vivo compared with unactivated cells.37 As such, they have
been identiﬁed as a population of memory NK cells. In
the present model of peritoneal immunization, nonspeciﬁc
tumor immune responses are observed even 60 days after
immunization, suggesting a memory NK or NKT cell
response. However, this response may differ from what has
been described by memory NK cells in other models. For
example, memory NK cells have been deﬁned in viral- and
hapten-speciﬁc immunity and under these circumstances are
antigen speciﬁc.38,39 The memory NK cells that have been
described after cytokine activation, however, are not gener-
ated against a speciﬁc target and are not antigen speciﬁc.37 It is
likely that thememory-like NK1.1þ cell population generated
after immunization with lethally irradiated Colon38 more
closely resembles this type of nonspeciﬁc memory NK cell.
Many of the possible modes of NK1.1þ cell activation
involve the presence of cytokines. Introduction of particu-
late antigen alone into the peritoneal cavity can induce an
immune response in the peritoneal cavity,3 but immuniza-
tion with lethally irradiated tumor cells provides more than
just a source of antigen. Administration of a lethal dose of
radiation results in the generation of DNA damage that
prevents further cell divisions, which is why it is termed
lethal. Despite the terminal fate of lethally irradiated cells,1326they are not immediately destroyed and are still capable of
producing various metabolic products. In fact, irradiation
has been shown to induce the production of various factors
in tumor cells and other cell types, which can result in
radiation-mediated effects outside the cells directly receiving
radiation, termed bystander responses. These factors include
products that are directly inﬂammatory, such as TNF-a and
IL-6, and products that can induce inﬂammatory responses in
other cells, such as reactive oxygen species and danger-
associated molecular patterns.40e43 These danger-associated
molecular patterns subsequently alert the immune system
by signaling immune cells through receptors such as the Toll-
like receptors, resulting in the formation of a proinﬂammatory
response. Although activation of the omentum by other mech-
anisms has been demonstrated to result in an anti-inﬂammatory
response,44 we believe that it is the production of these factors
after irradiation that promotes the formation of a proinﬂam-
matory immune response, resulting in tumor control/rejection.
In addition, macrophages, which are numerous in the
peritoneal cavity, have been suggested to be a critical cell
type in propagating bystander responses in vivo.43,45 These
bystander responses may be acting as an adjuvant that is
critical in promoting the nonspeciﬁc antitumor response, and,
thus, introduction of irradiated tumor cells into the peritoneal
cavity could be expected to have pleiotropic effects. First, the
inﬂammatory mediators released directly by the tumor cells
could aid in activating an immune response and/or relieving
the suppressive factors present in the peritoneal cavity and on
the omentum. Second, phagocytosis of the tumor cells would
be expected to activate the macrophage population and result
in the production of cytokines and additional inﬂammatory
mediators that can further act on other cell populations in the
peritoneal cavity to modify the immune response. Thus,
immunization with lethally irradiated Colon38 results in a
compounding inﬂammatory response, which would be con-
sistent with the marked changes we observed in the structure
and cell composition of the omentum after immunization and
could result in induction of nonspeciﬁc NK cell memory.
The current standard practice for diagnosis of peritoneal
metastasis is omentectomy13,14; however, the potential for
generating a productive antitumor immune response in the
peritoneal cavity has largely been ignored. These data involve
immunization with syngeneic tumors before tumor challenge,
which is generally not feasible in the clinical setting. How-
ever, such treatment could be delivered at the same time as
primary tumor treatment as a means of preventing or limiting
the formation or further growth ofmetastatic foci. Because the
antitumor response we could generate was nonspeciﬁc, it
would be theoretically possible to immunize patients who
have a high probability of peritoneal tumor metastasis to
prevent tumor growth in the peritoneal cavity. Important to
either this direct translation or immunotherapy derived from
these data would be a greater understanding of themechanism
by which NK1.1þ cells are activated to induce tumor cell
death and the mechanism by which this killing occurs. The
present immunization has a very complex composition, andajp.amjpathol.org - The American Journal of Pathology
Peritoneal Antitumor Immunityan understanding of which of these components are essential
to generate this nonspeciﬁc antitumor response would be
critical in the generation of a therapeutic treatment. In addi-
tion, if these components were better understood, it may be
possible to activate patient NK1.1þ cells ex vivo similar to IL-
2estimulated lymphokine-activated killer cells, which have
been used in multiple clinical trials.46 It is possible that only
NK1.1þ cells from the peritoneal cavity can elicit this type of
nonspeciﬁc antitumor response. There are several reports that
demonstrate unique populations of NK cells located speciﬁ-
cally in the liver that have either memory or antitumor func-
tions.47,48 The NK cells in the peritoneal cavity may represent
a similar scenario in which cells capable of this type of
nonspeciﬁc tumor response are located in this speciﬁc micro-
environment. Our current studies seek to address these issues
and further characterize this unusual antitumor response.
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